Background: Pazopanib is an effective first-line treatment for advanced renal cell carcinoma (RCC), but its efficacy and safety in the Vietnamese population are not well-documented. This study evaluates the outcomes and adverse effects of pazopanib at K Hospital, with a focus on the impact of initial dosing.

Methods: A retrospective and prospective study of 60 patients with advanced RCC treated with pazopanib between January 2018 and July 2024. The initial doses were 200mg, 400mg, 600mg, or 800mg. Primary endpoints were overall response rate (ORR) and disease control rate (DCR), with secondary endpoints including progression-free survival (PFS), overall survival (OS), and adverse events.

Results: The ORR was 45%, with 3.3% achieving complete response and 41.7% partial response. Median PFS was 13.1 months, and median OS was 21.5 months. The initial dose of pazopanib did not significantly affect OS (25.5 months for 800mg vs. 20.5 months for lower doses, p=0.945). Common adverse effects included elevated liver enzymes and fatigue.

Conclusions: Pazopanib is effective and well-tolerated in the Vietnamese population, with no significant impact of initial dosing on overall survival. Dose adjustments based on tolerability may be beneficial. Further research with larger samples and longer follow-up is needed to confirm these findings.

.